The "Wait and See" Era is Over: Earnings updates from 1/29 - 2/2

Investors stopped rewarding vague promises this week. They want hard numbers and actual resilience. We just saw another wave of earnings (Stryker, Thermo Fisher, Roche, Elevance, DaVita), and the message to the C-Suite is clear: Stop hiding behind "macro uncertainty" and tell us your plan.

Here is the reality check from the last few days:

1. You Have to Name the Number Stryker didn't flinch. They admitted tariffs will cost them $400M next year. But they also laid out exactly how they will offset it with better pricing and sales specialization. That is the new standard. If you can’t quantify your risk like Stryker did, investors assume you’re unprepared.

2. "Localizing" is the Only Safety Net Thermo Fisher and Roche proved that the only real hedge against trade wars is building where you sell. They are successfully decoupling their China operations from their US earnings. If your supply chain still relies on moving core products across borders, you are exposed.

3. Growth at All Costs is Dead Elevance Health is purposely cutting unprofitable members to save their margins. DaVita proved that value-based care isn't just a concept—it’s actually beating inflation. The market doesn't care how big you are anymore; they care if your revenue is actually profitable.

Open the document below for a detailed view of all companies covered in this analysis.

2026 Q4 Earnings Summary for Medical Device Execs.pdf

Download PDF • 128KB